CeriBell’s (NASDAQ:CBLL) Lock-Up Period To End on April 9th

CeriBell’s (NASDAQ:CBLL) lock-up period will expire on Wednesday, April 9th. CeriBell had issued 10,606,060 shares in its initial public offering on October 11th. The total size of the offering was $180,303,020 based on an initial share price of $17.00. After the expiration of the company’s lock-up period, company insiders and major shareholders will be able to sell their shares of the company.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the stock. Canaccord Genuity Group reissued a “buy” rating and set a $33.00 price objective on shares of CeriBell in a research note on Wednesday, February 26th. TD Cowen increased their target price on CeriBell from $31.00 to $36.00 and gave the company a “buy” rating in a report on Monday, December 9th. Six analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of “Buy” and a consensus target price of $32.60.

CeriBell Stock Performance

CeriBell stock opened at $18.77 on Wednesday. CeriBell has a 12-month low of $18.50 and a 12-month high of $32.75. The business’s 50-day moving average price is $22.21.

CeriBell (NASDAQ:CBLL) last announced its earnings results on Tuesday, February 25th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.08). The company had revenue of $18.53 million for the quarter, compared to analysts’ expectations of $17.55 million. As a group, equities research analysts expect that CeriBell will post -2.46 EPS for the current fiscal year.

Institutional Investors Weigh In On CeriBell

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Legal & General Group Plc purchased a new position in CeriBell during the fourth quarter worth about $32,000. Summit Investment Advisors Inc. purchased a new stake in CeriBell in the 4th quarter valued at about $33,000. Tower Research Capital LLC TRC acquired a new position in shares of CeriBell during the 4th quarter valued at about $37,000. BNP Paribas Financial Markets purchased a new position in shares of CeriBell during the 4th quarter worth about $43,000. Finally, PNC Financial Services Group Inc. acquired a new stake in shares of CeriBell in the fourth quarter worth approximately $47,000.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.